Latest news with #CARB-X
Yahoo
04-03-2025
- Business
- Yahoo
Centauri Therapeutics Selects First Clinical Candidate, for Immunotherapeutic Treatment of Gram-negative Bacterial Infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients LONDON, March 04, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company's Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug candidate will now be further developed ahead of progression to first in-human clinical studies. The lead candidate in the ABX-01 programme is a broad-spectrum antimicrobial peptide specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Preclinical studies have demonstrated the compound's activity against Gram-negative bacteria. "We are excited to enter the clinical development phase with the ABX-01 lead candidate, thanks to our dedicated team who have worked hard to advance our Alphamer platform to this crucial stage. The platform has the potential to address a vital gap in the current anti-infective treatment landscape, and we remain confident that our lead candidate will continue to demonstrate this as we progress towards a Phase I clinical trial," commented Dr Jennifer Schneider, CEO, Centauri Therapeutics. "We are proud to progress this molecule with the continuous support of our investors and our long-standing partner, CARB-X, for which we are grateful." Dr Helen Bright, CSO, Centauri Therapeutics, said: "Our focus at Centauri Therapeutics has always been on developing novel immune therapy approaches to expand treatment options for the most vulnerable, starting with the anti-infectives space. Reaching this stage highlights the potential of our disruptive technology, not only in anti-infectives, but also within the oncology and vaccines spaces. I look forward to working alongside our brilliant and highly motivated team to take us into this next phase of development." Centauri is now conducting regulatory preclinical activities to enable streamlined progression of its lead clinical candidate into a Phase I clinical trial. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. View source version on Contacts Katie Sign in to access your portfolio
Associated Press
17-02-2025
- Business
- Associated Press
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
ZURICH--(BUSINESS WIRE)--Feb 17, 2025-- , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus ( S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7. S. aureus infections pose a significant global health challenge, causing an estimated 1 million deaths annually. Notably, 90% of all community-acquired S. aureus infections are SSTIs. The absence of a vaccine to prevent S. aureus, coupled with only limited treatment options - particularly against multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA) - highlights the urgent need for effective preventive solutions. LimmaTech's vaccine candidate, LBT-SA7, is the first multivalent vaccine entirely based on secreted antigens to address this critical need. LBT-SA7 contains weakened forms of the pathogen's toxins, referred to as toxoids, designed to prevent infections by neutralizing the toxins secreted by S. aureus. This approach offers a promising solution to combat the widespread bacterial threat. LimmaTech started a Phase 1 clinical trial ( NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA). This first-in-human study aims to evaluate the safety and immunogenicity of LBT-SA7 against S. aureus. It is a randomized, double-blinded, and controlled dose-escalation study expected to enroll 130 healthy adults aged 18-50 years. Initial results are anticipated in the second half of 2025. 'Developing an S. aureus vaccine has long been a significant scientific challenge,' explained Dr. Patricia Martin-Killias, Chief Operating Officer of LimmaTech. 'We believe LBT-SA7 has the potential to provide a much-needed solution for those suffering from S. aureus infections. We are excited to launch the first-in-human clinical trial for LBT-SA7, bringing us closer to addressing an urgent global health challenge.' 'We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical development of our S. aureus vaccine candidate LBT-SA7 but also underscores the importance of our mission to develop efficient solutions for preventing microbial infections and protecting from their threatening consequences for affected people,' added Dr. Franz-Werner Haas, Chief Executive Officer of LimmaTech. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About Staphylococcus aureus Staphylococcus aureus ( S. aureus), a Gram-positive bacterial pathogen, affects approximately 30% of the human population while causing a spectrum of infections, from SSTI to severe conditions like pneumonia and bloodstream infections. S. aureus is the leading cause of antimicrobial resistance (AMR)-attributed fatalities with community-acquired and hospital-acquired infections being the most prevalent. SSTIs caused by S. aureus range from mild to severe and entail microbial invasion into the skin layers and underlying soft tissues. Traditional antibiotic treatments, both oral therapy and intravenous administration reserved for severe cases, have become increasingly less effective due to the rise of antibiotic resistance. S. aureus has been designated as a 'high priority' pathogen by the World Health Organization (WHO), underscoring the urgency for innovative vaccine approaches and effective treatment strategies. About LimmaTech Biologics AG LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit Franz-Werner Haas, CEO For media enquiries Jacob Verghese or Anja Heuer Trophic Communications Phone: +49 151 7441 6179 KEYWORD: SWITZERLAND EUROPE SOURCE: LimmaTech Biologics AG Copyright Business Wire 2025. PUB: 02/17/2025 04:00 AM/DISC: 02/17/2025 04:02 AM
Yahoo
17-02-2025
- Health
- Yahoo
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 ZURICH, February 17, 2025--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7. S. aureus infections pose a significant global health challenge, causing an estimated 1 million deaths annually. Notably, 90% of all community-acquired S. aureus infections are SSTIs. The absence of a vaccine to prevent S. aureus, coupled with only limited treatment options - particularly against multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA) - highlights the urgent need for effective preventive solutions. LimmaTech's vaccine candidate, LBT-SA7, is the first multivalent vaccine entirely based on secreted antigens to address this critical need. LBT-SA7 contains weakened forms of the pathogen's toxins, referred to as toxoids, designed to prevent infections by neutralizing the toxins secreted by S. aureus. This approach offers a promising solution to combat the widespread bacterial threat. LimmaTech started a Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA). This first-in-human study aims to evaluate the safety and immunogenicity of LBT-SA7 against S. aureus. It is a randomized, double-blinded, and controlled dose-escalation study expected to enroll 130 healthy adults aged 18-50 years. Initial results are anticipated in the second half of 2025. "Developing an S. aureus vaccine has long been a significant scientific challenge," explained Dr. Patricia Martin-Killias, Chief Operating Officer of LimmaTech. "We believe LBT-SA7 has the potential to provide a much-needed solution for those suffering from S. aureus infections. We are excited to launch the first-in-human clinical trial for LBT-SA7, bringing us closer to addressing an urgent global health challenge." "We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical development of our S. aureus vaccine candidate LBT-SA7 but also underscores the importance of our mission to develop efficient solutions for preventing microbial infections and protecting from their threatening consequences for affected people," added Dr. Franz-Werner Haas, Chief Executive Officer of LimmaTech. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About Staphylococcus aureus Staphylococcus aureus (S. aureus), a Gram-positive bacterial pathogen, affects approximately 30% of the human population while causing a spectrum of infections, from SSTI to severe conditions like pneumonia and bloodstream infections. S. aureus is the leading cause of antimicrobial resistance (AMR)-attributed fatalities with community-acquired and hospital-acquired infections being the most prevalent. SSTIs caused by S. aureus range from mild to severe and entail microbial invasion into the skin layers and underlying soft tissues. Traditional antibiotic treatments, both oral therapy and intravenous administration reserved for severe cases, have become increasingly less effective due to the rise of antibiotic resistance. S. aureus has been designated as a "high priority" pathogen by the World Health Organization (WHO), underscoring the urgency for innovative vaccine approaches and effective treatment strategies. About LimmaTech Biologics AG LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit View source version on Contacts LimmaTech Biologics AG Franz-Werner Haas, CEOE-Mail: media@ For media enquiries Jacob Verghese or Anja HeuerTrophic CommunicationsPhone: +49 151 7441 6179Email: limmatech@ Sign in to access your portfolio
